Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma-Reference-Cited by-同舟云学术

Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma

Published:2013-03-14 Issue:5 Volume:90 Page:420-425
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Moore Sally¹,Atwal Sangeeta²,Sachchithanantham Sajitha³,Streetly Matthew⁴,Khan Iftekhar⁵,Percy Laura¹,Narat Santosh³,D'Sa Shirley¹,Rabin Neil¹,Johnston Rosalynd³,Schey Steve²,Yong Kwee¹

Affiliation:

1. Department of Haematology; University College London Hospital (UCLH); London; UK

2. Department of Haematology ; Kings College Hospital (KCH); London; UK

3. Department of Haematology; Worthing Hospital; Western & Sussex Hospitals NHS Trust; London; UK

4. Department of Haematology ; Guy's and St Thomas' Trust (GSTT); London; UK

5. Cancer Trials Centre; University College London; London; UK

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12070/fullpdf

Reference23 articles.

1. A phase 2 study of bortezomib in relapsed, refractory myeloma;Richardson;N Engl J Med,2003

2. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma;Jagannath;Br J Haematol,2004

3. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma;Richardson;N Engl J Med,2005

4. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N Eng J Med,2008

5. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy;Richardson;J Clin Oncol,2009

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Major cardiovascular events in long-term multiple myeloma survivors: a Korean case–control study (the CAREMM-2105 study);Clinical and Experimental Medicine;2024-06-12

2. Major cardiovascular events in long-term multiple myeloma survivors: A Korean case- control study (The CAREMM-2105 study);2024-04-04

3. Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems;Journal of Pharmaceutical Investigation;2021-05-08

4. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance;British Journal of Cancer;2020-11-30

5. Reduced weekly subcutaneous doses of bortezomib in combination with cyclophosphamide and dexamethasone for newly diagnosed multiple myeloma;Journal of Research in Pharmacy Practice;2020